{
    "nct_id": "NCT03334617",
    "official_title": "An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Patients whose tumour samples have targetable alterations in EGFR and/or ALK at initial diagnosis are excluded. In addition, patients whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).\n* Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control.\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies.\n* Patient has spinal cord compression or symptomatic brain metastases.\n* Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Patients may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Î’ ligand (RANKL) inhibitors for the treatment of bone metastases.\n* history of active primary immunodeficiency",
    "miscellaneous_criteria": "Inclusion criteria:\n\n* At least 18 years of age at the time of signing the informed consent form.\n* Patient must have histologically or cytologically confirmed metastatic or locally advanced and recurrent NSCLC which is progressing.\n* Patients eligible for second- or later-line therapy, who must have received an antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The patient must have had disease progression on a prior line of antiPD1/PD-L1 therapy.\n* ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.\n* Patient must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed.\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients."
}